HIV vaccine clinical trials: An overview

Jackline Odhiambo

Volume 27, Issue 1 - Vaccines and Immunotherapies

HIV vaccine clinical trials: An overview

Author: Jackline Odhiambo

Abstract

More than 30 years after the discovery of the human immunodeficiency virus as the agent that causes AIDS, an effective vaccine against this deadly disease has yet to be developed. The pathway to the development of a vaccine has been riddled with challenges, many unique to HIV itself. As a result, advocates, scientists, and funders have had to move away from a “home run” philosophy that had anticipated early success. Nonetheless, much has been learned along the way about the genetic diversity of the virus, the limitations of animal studies, and the cultural infra structure and regulatory challenges involved in testing HIV vaccines. The application of coordinated approaches to face the difficulties outlined in this article is a logical way forward in developing a vaccine. Then even more progress can be made, in spite of all the uncertainties, toward the achievement of a successful vaccine.

Download the full article

References

Hiv.gov. HIV Vaccines. 2017 [cited 2017 Nov 11]. Available from: https://www.hiv.gov/hiv-basics/hiv-prevention/potential-future-options/hiv-vaccines
Kurth AE, Celum C, Baeten JM, Vermund SH, Wasserheit JN. Combination HIV prevention: significance, challenges, and opportunities. Current HIV/AIDS reports. 2011;8(1):62–72.
Stover J, Bollinger L, Hecht R, Williams C, Roca E. The impact of an AIDS vaccine in developing countries: a new model and initial results. Health Aff. 2007;26(4):1147–58.
Sheets RL, Zhou T, Knezevic I. Review of efficacy trials of HIV-1/AIDS vaccines and regulatory lessons learned: a review from a regulatory perspective. Biologicals. 2016;44(2):73–89.
The History of Vaccines: An Educational Resource by The College of Physicians of Philadelphia. Vaccines for Sexually Transmitted Diseases. 2017 [cited 2017 Nov 11]. Available from: https://www. historyofvaccines.org/content/articles/ vaccines-sexually-transmitted-diseases
Follmann D, Duerr A, Tabet S, Gilbert P, Moodie Z, Fast P, et al. J Acquir Immune Defic Syndr. 2007;44(1):49–60.
HIV/AIDS vax - An IAVI Report Bulletin. Understanding Vaccine Trials: How are AIDS vaccines tested? 2003;1(1):4. Available from: http://www.vaxreport.org/vax-1-1-august- 2003/869-understanding-vaccine-trials.
Esparza J. An HIV vaccine: how and when? Bull World Health Organ. 2001;79(12):1133–7.
The History of Vaccines: An Educational Resource by The College of Physicians of Philadelphia. Vaccine Development, Testing, and Regulation. 2017 [cited 2017 Nov 04] Available from: https://www.historyofvaccines.org/content/articles/vaccine-development-testing-and-regulation
Black S. The costs and effectiveness of large Phase III pre-licensure vaccine clinical trials. Expert Rev Vaccines. 2015;14(12):1543–8.
Wu X, Wang C, O’Dell S, Li Y, Keele BF, Yang Z, et al. Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site. J Virol. 2012;86(10):5844–56.
AMP Study. About AMP: What is the AMP Study? 2017 [cited 2017 Nov 30]. Available from: https://ampstudy.org.za/about
U.S. Military HIV Research Program. RV144 Trial. 2017 [cited 2017 Dec 02]. Available from: https://www.hivresearch.org/rv144-trial
Uhambo: A Journey of Hope to Prevent HIV. What is HVTN 702? 2017 [cited 2017 Nov 30]. Available from: http://www.uhambo.org.za/about
Imbokodo: Stand up to HIV. What is Imbokodo? 2017 [cited 2017 Nov 30]. Available from: https://www.imbokodo.org.za/about
Vardas E, Buttò S, Glashoff R, Malnati MS, Poli G, Clerici M. Preparing for phase II/III HIV vaccine trials in Africa. Microbes Infect. 2005;7(14):1436–44.
UNAIDS Guidance Document: Ethical considerations in HIV preventive vaccine research. 2000
Scientific considerations for the regulation and clinical evaluation of HIV/AIDS preventive vaccines: report from a WHOUNAIDS Consultation 13-15 March 2001, Geneva, Switzerland. AIDS. 2002;16(10):W15–25.
Okpokoro E, Osawe S, Datong P, Yakubu A, Ukpong M, Orhii P, et al. Preparing for HIV vaccine trials in Nigeria: building the capacity of the community and national coordinating, regulatory and ethical bodies. J AIDS Clin Res. 2013;4(12):260.
National Institute of Environmental Health Sciences. Institutional Biosafety Committee. 2017 [cited 2017 Dec 03]. Available from: https://www.niehs.nih.gov/about/boards/ibc/index.cfm
Department of Agriculture, Forestry and Fisheries: Republic of South Africa. Biosafety Notifications. 2017 [cited 2017 Dec 03]. Available from: http://www.daff.gov.za/daffweb3/Branches/Agricultural-Production-Health-Food-Safety/Genetic-Resources/Biosafety/Biosafety-Clearing-House
Barouch DH, Picker LJ. Novel vaccine vectors for HIV-1. Nat Rev Microbiol. 2014;12(11):765–71.
Excler JL, Michael NL. Lessons from HIV- 1 vaccine efficacy trials. Curr Opin HIV AIDS. 2016;11(6):607–13.
HIV Vaccine Trials Network. Getting the Right Test for HIV. [cited 2017 Nov 30]. Available from: http://www.hvtn.org/en/participants/visp-hiv-testing.html

Volume 27, Issue 1 - Vaccines and Immunotherapies

HIV vaccine clinical trials: An overview

Author: Jackline Odhiambo

Abstract

References

Search

Articles

Member Login

Links

Editoral Board